Another emerging DXd-based ADC, raludotatug DXd (R-DXd, DS-6000a), targets cadherin-6 (CDH6) and is being evaluated in renal and ovarian cancers, where CDH6 expression is prevalent [26]. Here, CDH6 is linked to ovarian cancer.